TY - JOUR T1 - Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study JF - Annals of the Rheumatic Diseases JO - Ann Rheum Dis SP - 1083 LP - 1086 DO - 10.1136/ard.2010.142042 VL - 70 IS - 6 AU - Amelia Ruffatti AU - Teresa Del Ross AU - Manuela Ciprian AU - Maria T Bertero AU - Sciascia Salvatore AU - Salvatore Scarpato AU - Carlomaurizio Montecucco AU - Silvia Rossi AU - Paola Caramaschi AU - Domenico Biasi AU - Andrea Doria AU - Mariaelisa Rampudda AU - Nuzzo Monica AU - Fabio Fischetti AU - Ugo Picillo AU - Antonio Brucato AU - Elisa Salvan AU - Pengo Vittorio AU - Pierluigi Meroni AU - Angela Tincani AU - Antiphospholipid Syndrome Study Group of the Italian Society of Rheumatology Y1 - 2011/06/01 UR - http://ard.bmj.com/content/70/6/1083.abstract N2 - Objectives To assess risk factors for a first thrombotic event in confirmed antiphospholipid (aPL) antibody carriers and to evaluate the efficacy of prophylactic treatments. Methods Inclusion criteria were age 18–65 years, no history of thrombosis and two consecutive positive aPL results. Demographic, laboratory and clinical parameters were collected at enrolment, once a year during the follow-up and at the time of the thrombotic event, whenever that occurred. Results 258 subjects were prospectively observed between October 2004 and October 2008. The mean±SD follow-up was 35.0±11.9 months (range 1–48). A first thrombotic event (9 venous, 4 arterial and 1 transient ischaemic attack) occurred in 14 subjects (5.4%, annual incidence rate 1.86%). Hypertension and lupus anticoagulant (LA) were significantly predictive of thrombosis (both at p<0.05) and thromboprophylaxis was significantly protective during high-risk periods (p<0.05) according to univariate analysis. Hypertension and LA were identified by multivariate logistic regression analysis as independent risk factors for thrombosis (HR 3.8, 95% CI 1.3 to 11.1, p<0.05, and HR 3.9, 95% CI 1.1 to 14, p<0.05, respectively). Conclusions Hypertension and LA are independent risk factors for thrombosis in aPL carriers. Thromboprophylaxis in these subjects should probably be limited to high-risk situations. ER -